
At an extraordinary general meeting on Tuesday, biotech firm Orphazyme elected a new board member, Andrew Mercieca.
Mercieca was proposed to fill the vacancy left by Catherine Moukheibir back in December, and, until formally elected, he was also appointed observer and consultant to the board.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app